Anika Therapeutics Net Worth
Anika Therapeutics Net Worth Breakdown | ANIK |
Anika Therapeutics Net Worth Analysis
Anika Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Anika Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Anika Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Anika Therapeutics' net worth analysis. One common approach is to calculate Anika Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Anika Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Anika Therapeutics' net worth. This approach calculates the present value of Anika Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Anika Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Anika Therapeutics' net worth. This involves comparing Anika Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Anika Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Anika Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Anika Therapeutics' net worth research are outlined below:
| Anika Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 119.91 M. Net Loss for the year was (56.38 M) with profit before overhead, payroll, taxes, and interest of 76.6 M. | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by David Colleran of 13669 shares of Anika Therapeutics subject to Rule 16b-3 |
Anika Therapeutics Quarterly Good Will |
|
Anika Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Anika Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Anika Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Anika Therapeutics Target Price Consensus
Anika target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Anika Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Anika analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Anika stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Anika Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAnika Therapeutics Target Price Projection
Anika Therapeutics' current and average target prices are 15.62 and 26.50, respectively. The current price of Anika Therapeutics is the price at which Anika Therapeutics is currently trading. On the other hand, Anika Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Anika Therapeutics Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Anika Therapeutics Target Price
Know Anika Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Anika Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anika Therapeutics backward and forwards among themselves. Anika Therapeutics' institutional investor refers to the entity that pools money to purchase Anika Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stonepine Capital Management Llc | 2024-12-31 | 238.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 189.2 K | Meros Investment Management, Lp | 2024-12-31 | 177.7 K | D. E. Shaw & Co Lp | 2024-12-31 | 153.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 137.5 K | Northern Trust Corp | 2024-12-31 | 123.2 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 119 K | Globeflex Capital, L.p. | 2024-12-31 | 87.6 K | Jpmorgan Chase & Co | 2024-12-31 | 82.5 K | Trigran Investments Inc | 2024-12-31 | 2 M | Blackrock Inc | 2024-12-31 | 1.6 M |
Follow Anika Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 226.11 M.Market Cap |
|
Project Anika Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.28) | |
| Return On Capital Employed | (0.03) | (0.03) | |
| Return On Assets | (0.28) | (0.26) | |
| Return On Equity | (0.37) | (0.35) |
When accessing Anika Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Anika Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Anika Therapeutics' profitability and make more informed investment decisions.
Evaluate Anika Therapeutics' management efficiency
Anika Therapeutics has return on total asset (ROA) of (0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0482) %, meaning that it created substantial loss on money invested by shareholders. Anika Therapeutics' management efficiency ratios could be used to measure how well Anika Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.28 this year. Return On Capital Employed is expected to rise to -0.03 this year. Change To Liabilities is expected to rise to about 3.6 M this year, although the value of Total Current Liabilities will most likely fall to about 12.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.46 | 6.69 | |
| Tangible Book Value Per Share | 9.81 | 5.66 | |
| Enterprise Value Over EBITDA | (41.30) | (39.24) | |
| Price Book Value Ratio | 1.57 | 1.71 | |
| Enterprise Value Multiple | (41.30) | (39.24) | |
| Price Fair Value | 1.57 | 1.71 | |
| Enterprise Value | 511.9 M | 537.5 M |
The operational strategies employed by Anika Therapeutics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 1.6274 | Revenue | Quarterly Revenue Growth (0.29) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anika Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anika Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anika Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anika Therapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 17th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 12th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of February 2025 Other Reports | ViewVerify |
Anika Therapeutics Earnings Estimation Breakdown
The calculation of Anika Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Anika Therapeutics is estimated to be 0.09 with the future projection ranging from a low of 0.09 to a high of 0.09. Please be aware that this consensus of annual earnings estimates for Anika Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.09 Lowest | Expected EPS | 0.09 Highest |
Anika Therapeutics Earnings Projection Consensus
Suppose the current estimates of Anika Therapeutics' value are higher than the current market price of the Anika Therapeutics stock. In this case, investors may conclude that Anika Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Anika Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 2 | 51.29% | -0.03 | 0.09 | -0.6 |
Anika Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Anika Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Anika Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Anika Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Anika Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Anika Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Anika Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Anika Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Anika Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-11 | 2024-12-31 | 0.09 | -0.03 | -0.12 | 133 | ||
2024-10-31 | 2024-09-30 | -0.01 | -0.25 | -0.24 | 2400 | ||
2024-08-08 | 2024-06-30 | 0.05 | -0.01 | -0.06 | 120 | ||
2024-05-08 | 2024-03-31 | -0.19 | -0.31 | -0.12 | 63 | ||
2024-03-13 | 2023-12-31 | -0.26 | -4.3 | -4.04 | 1553 | ||
2023-11-02 | 2023-09-30 | -0.37 | -0.45 | -0.08 | 21 | ||
2023-08-08 | 2023-06-30 | -0.27 | -0.19 | 0.08 | 29 | ||
2023-05-09 | 2023-03-31 | -0.3 | -0.47 | -0.17 | 56 | ||
2023-03-06 | 2022-12-31 | -0.24 | -0.34 | -0.1 | 41 | ||
2022-11-08 | 2022-09-30 | -0.25 | -0.15 | 0.1 | 40 | ||
2022-08-03 | 2022-06-30 | -0.23 | -0.2 | 0.03 | 13 | ||
2022-05-05 | 2022-03-31 | -0.36 | -0.2 | 0.16 | 44 | ||
2022-03-08 | 2021-12-31 | -0.25 | -0.4 | -0.15 | 60 | ||
2021-11-04 | 2021-09-30 | -0.21 | 0.04 | 0.25 | 119 | ||
2021-08-05 | 2021-06-30 | -0.15 | 0.45 | 0.6 | 400 | ||
2021-05-06 | 2021-03-31 | -0.12 | 0.2 | 0.32 | 266 | ||
2021-03-04 | 2020-12-31 | 0.14 | 0.12 | -0.02 | 14 | ||
2020-11-04 | 2020-09-30 | -0.01 | -0.45 | -0.44 | 4400 | ||
2020-07-30 | 2020-06-30 | -0.24 | -0.37 | -0.13 | 54 | ||
2020-05-07 | 2020-03-31 | -0.06 | 0.06 | 0.12 | 200 | ||
2020-02-20 | 2019-12-31 | 0.42 | 0.43 | 0.01 | 2 | ||
2019-10-24 | 2019-09-30 | 0.39 | 0.64 | 0.25 | 64 | ||
2019-07-24 | 2019-06-30 | 0.39 | 0.68 | 0.29 | 74 | ||
2019-05-02 | 2019-03-31 | 0.19 | 0.31 | 0.12 | 63 | ||
2019-02-21 | 2018-12-31 | 0.33 | 0.54 | 0.21 | 63 | ||
2018-10-24 | 2018-09-30 | 0.31 | 0.53 | 0.22 | 70 | ||
2018-07-25 | 2018-06-30 | 0.33 | 0.68 | 0.35 | 106 | ||
2018-05-02 | 2018-03-31 | 0.16 | -0.46 | -0.62 | 387 | ||
2018-02-21 | 2017-12-31 | 0.44 | 0.38 | -0.06 | 13 | ||
2017-10-25 | 2017-09-30 | 0.45 | 0.46 | 0.01 | 2 | ||
2017-07-26 | 2017-06-30 | 0.44 | 0.76 | 0.32 | 72 | ||
2017-05-03 | 2017-03-31 | 0.38 | 0.37 | -0.01 | 2 | ||
2017-02-15 | 2016-12-31 | 0.53 | 0.54 | 0.01 | 1 | ||
2016-10-26 | 2016-09-30 | 0.47 | 0.59 | 0.12 | 25 | ||
2016-07-27 | 2016-06-30 | 0.44 | 0.57 | 0.13 | 29 | ||
2016-04-27 | 2016-03-31 | 0.28 | 0.45 | 0.17 | 60 | ||
2016-02-24 | 2015-12-31 | 0.6 | 0.72 | 0.12 | 20 | ||
2015-10-28 | 2015-09-30 | 0.35 | 0.55 | 0.2 | 57 | ||
2015-07-29 | 2015-06-30 | 0.34 | 0.51 | 0.17 | 50 | ||
2015-04-28 | 2015-03-31 | 0.21 | 0.23 | 0.02 | 9 | ||
2015-02-25 | 2014-12-31 | 0.48 | 0.51 | 0.03 | 6 | ||
2014-10-29 | 2014-09-30 | 0.33 | 0.4 | 0.07 | 21 | ||
2014-07-30 | 2014-06-30 | 0.57 | 0.6 | 0.03 | 5 | ||
2014-04-29 | 2014-03-31 | 0.25 | 0.97 | 0.72 | 288 | ||
2014-02-26 | 2013-12-31 | 0.42 | 0.44 | 0.02 | 4 | ||
2013-10-30 | 2013-09-30 | 0.16 | 0.33 | 0.17 | 106 | ||
2013-07-31 | 2013-06-30 | 0.23 | 0.4 | 0.17 | 73 | ||
2013-05-01 | 2013-03-31 | 0.17 | 0.2 | 0.03 | 17 | ||
2013-02-27 | 2012-12-31 | 0.24 | 0.42 | 0.18 | 75 | ||
2012-10-30 | 2012-09-30 | 0.17 | 0.12 | -0.05 | 29 | ||
2012-08-01 | 2012-06-30 | 0.16 | 0.26 | 0.1 | 62 | ||
2012-05-03 | 2012-03-31 | 0.17 | 0.14 | -0.03 | 17 | ||
2012-02-29 | 2011-12-31 | 0.13 | 0.21 | 0.08 | 61 | ||
2011-11-02 | 2011-09-30 | 0.11 | 0.22 | 0.11 | 100 | ||
2009-10-27 | 2009-09-30 | 0.1 | 0.13 | 0.03 | 30 | ||
2009-07-22 | 2009-06-30 | 0.08 | 0.08 | 0.0 | 0 | ||
2009-04-29 | 2009-03-31 | 0.09 | 0.05 | -0.04 | 44 | ||
2009-03-05 | 2008-12-31 | 0.13 | 0.1 | -0.03 | 23 | ||
2008-11-03 | 2008-09-30 | 0.11 | 0.1 | -0.01 | 9 | ||
2008-07-22 | 2008-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2008-04-30 | 2008-03-31 | 0.09 | 0.05 | -0.04 | 44 | ||
2008-03-05 | 2007-12-31 | 0.14 | 0.15 | 0.01 | 7 | ||
2007-11-05 | 2007-09-30 | 0.15 | 0.16 | 0.01 | 6 | ||
2007-07-24 | 2007-06-30 | 0.12 | 0.12 | 0.0 | 0 | ||
2007-04-26 | 2007-03-31 | 0.11 | 0.11 | 0.0 | 0 | ||
2007-02-28 | 2006-12-31 | 0.11 | 0.09 | -0.02 | 18 | ||
2006-10-24 | 2006-09-30 | 0.11 | 0.12 | 0.01 | 9 | ||
2006-07-24 | 2006-06-30 | 0.09 | 0.12 | 0.03 | 33 | ||
2006-04-25 | 2006-03-31 | 0.08 | 0.08 | 0.0 | 0 | ||
2006-03-02 | 2005-12-31 | 0.04 | 0.07 | 0.03 | 75 | ||
2005-10-18 | 2005-09-30 | 0.1 | 0.22 | 0.12 | 120 | ||
2005-07-27 | 2005-06-30 | 0.1 | 0.12 | 0.02 | 20 | ||
2005-04-27 | 2005-03-31 | 0.08 | 0.1 | 0.02 | 25 | ||
2005-02-23 | 2004-12-31 | 0.06 | 0.15 | 0.09 | 150 | ||
2004-10-29 | 2004-09-30 | 0.06 | 0.08 | 0.02 | 33 | ||
2004-08-06 | 2004-06-30 | 0.05 | 0.07 | 0.02 | 40 | ||
2004-04-29 | 2004-03-31 | 0.04 | 0.07 | 0.03 | 75 | ||
2000-03-15 | 1999-12-31 | 0.02 | 0.04 | 0.02 | 100 | ||
1999-10-21 | 1999-09-30 | 0.01 | 4.0E-4 | -0.0096 | 96 | ||
1999-07-22 | 1999-06-30 | 0.02 | 0.04 | 0.02 | 100 | ||
1999-04-21 | 1999-03-31 | 0.03 | 0.03 | 0.0 | 0 | ||
1999-02-25 | 1998-12-31 | 0.1 | 0.07 | -0.03 | 30 | ||
1998-10-22 | 1998-09-30 | 0.05 | 0.07 | 0.02 | 40 | ||
1998-07-21 | 1998-06-30 | 0.05 | 0.22 | 0.17 | 340 | ||
1998-04-15 | 1998-03-31 | 0.06 | 0.06 | 0.0 | 0 | ||
1998-02-24 | 1997-12-31 | 0.41 | 0.35 | -0.06 | 14 | ||
1997-10-23 | 1997-09-30 | 0.03 | -0.05 | -0.08 | 266 | ||
1997-08-21 | 1997-06-30 | 0.02 | 0.05 | 0.03 | 150 |
Anika Therapeutics Corporate Management
| Ian McLeod | VP Officer | Profile | |
| James Chase | Senior Marketing | Profile | |
| Bart Bracy | VP Americas | Profile | |
| Lisa Funiciello | Vice Resources | Profile | |
| Mark Namaroff | Executive Communications | Profile | |
| Michael CPA | Executive Officer | Profile | |
| Charles III | VP Counsel | Profile |
Already Invested in Anika Therapeutics?
The danger of trading Anika Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Anika Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Anika Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Anika Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (0.60) | Revenue Per Share | Quarterly Revenue Growth (0.29) | Return On Assets |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.